Kind of makes one wonder where all the alleged profits from trading went?
“Gain on sale of trading securities 340,020”
Here is the break down of the trades...
Do you see the “investments” that the shareholders were never told about???
(Or was that in another bs PR that I didn’t bother to read?)
I guess that’s where the gains went?
BSethie is underwater with both of those new “investments”...
“During the year ended March 31, 2018, the Company’s investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company’s investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the three months ended June 30, 2017, there was a comprehensive gain recorded of $1,250.
(b) On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (“VTGN”). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the three months ended June 30, 2018, the Company purchased 59,380 shares of VTGN for $61,254 (average price per share of $1.03 per share). The Company sold 72,380 shares of VTGN for $99,161 ($1.37 per share) for a realized loss of $14,686. The unrealized loss for the three months ended June 30, 2018 was $9,255.
(c) The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company is in possession of the registered securities as of the closing date. The Company’s investment in BLINK common stock and warrants had a cost of $191,150, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $149,975 (average price per share of $3.66). The Company sold its total holding of 86,018 shares of BLINK for $371,986 (average price per share of $4.32) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $476,695 (average price per warrant of $1.60) realizing a gain of $305,381.
(d) On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in ATYU had a cost of $82,270, unrealized loss of $37,677 and a fair value of $119,947 at March 31, 2018. During the three months ended June 30, 2018, the Company purchased 260,000 shares of AYTU for a $98,830 (average price per share $0.38). During the three months ended June 30, 2018, the Company sold 48,300 shares of AYTU for $26,752 ($0.55 per share). During the three months ended June 30, 2018, the Company had an unrealized loss of $55,605 on this holding.
(e) On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the three months ended June 30, 2018, the Company purchased 150,000 shares of LTBR for $160,441 (average of $1.07 per share.) During the three months ended June 30, 2018, the Company sold 62,405 shares of LTBR for $98,869 (average price per share of $1.58) realizing a gain of $19,182. During the three months ended June 30, 2018, the Company had an unrealized loss of $8,164 on this holding.
(f) During the three months ended June 30, 2018, the Company purchased 375,000 shares of Pulmatix Inc. (PULM) for $194,812 (average per share price of $0.52. During the three months ended June 30, 2018, the Company had an unrealized loss of $28,230 on this holding.
(g) During the three months ended June 30, 2018, the Company purchased 35,000 shares of Axovant Sciences Ltd. (AXON) for $89,113 (average share price of $2.55). During the three months ended June 30, 2018, the Company had an unrealized loss of $11,025 on this holding.
At June 30, 2018, the Company held warrants for AYTU Bioscience to purchase 111,100 common shares at a strike price of $0.54 with an expiration of March 6, 2023. At June 30, 2018 these warrants were out of the money by $0.278 per share. Since these shares are not publicly traded and therefore are not highly liquid the Company has chosen not to recognize the unrealized gain in this security.
At June 30, 2018, the Company held warrants for VistaGen Therapeutics, Inc. to purchase 320,000 shares of common stock at a strike price of $1.50 per share, with an expiration of December 13, 2022. At June 30, 2018 these warrants were out of the money by $0.13 per share. Since these warrants are not publicly traded and, therefore, are not highly liquid the Company has chosen not to recognize the unrealized gain or loss in this security.
Digital Currency
During the year ended March 31, 2018, the Company completed cumulative purchases in the Groestlcoin cryptocurrency in the aggregate amount of $35,000 for 27,919.133 units ($0.79 per unit). (Crypto Currency Code: GRS). The purchase of this currency cannot be executed directly using $USD. The Company must purchase Bitcoin (BTC) and then purchase the Groestlcoin cryptocurrency by using BTC. This two-step process generated actual losses or gains on the purchase of Groestlcoin. For the year ended March 31, 2018 the Company realized a loss of $2,859 on exchange from BTC reflected as other operation income. The investment in Groestlecoin has a cost of $31,481 net of fees, unrealized loss of $9,425 and a fair value of $22,056.
During the three months ended June 30, 2018, the Company completed a purchase in the Groestlcoin cryptocurrency in the aggregate amount of $8,000 for 11,922.81 units ($0.65.69 per unit). For the three months ended June 30, 2018 the Company realized a loss of $37 on exchange from BTC reflected as other operation income. The investment in Groestlecoin has a cost of $39,862 net of fees, unrealized loss of $5,572 and a fair value of $24,316.”
Too funny
